• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

ABBV STOCK HITS RECORD ALL TIME HIGH

Quote




anonymous said:
Not so fast genuises ! A few more adverse events or ANY negative results in trials of Rova-T, Elagoix, Upadacitinib, or Risankizumab combined with the clock ticking down on Humira could push this stock back to the $60s so fast your head will spin. Let's hope not, but smart investors won't EVER rule it out.
Click to expand...

And so it comes to pass Ha Hah Hah Told Y'all
AbbVie Inc. ABBV, -10.64% shares dropped 11.7% in early trade Thursday after the company said it will not try for accelerated approval of rovalpituzumab tesirine in third-line relapsed/refractory small cell lung cancer based on the drug's results in a phase 2 trial and the "magnitude of effect across multiple parameters." The decision was made after consulting with the Food and Drug Administration,the company said. AbbVie said it does still believe the drug, also called Rova-T, has potential in small cell lung cancer and other cancers expressing the DLL3 protein, and Rova-T continues to be studied in ongoing phase 3 trials for first-line and second-line small cell lung cancer. AbbVie bought Rova-T in a $5.8 billion deal for Stemcentrx in 2016; Rova-T was the company's lead asset. AbbVie shares have surged 14.5% over the last three months but dropped nearly 3% month-to-date. The S&P 500 SPX, -1.06% has surged 1.1% over the last three months and declined 0.1% month-to-date.
 




AbbVie Inc
NYSE: ABBV - Mar 22,
$100.06 USD DOWN $12.39 (11.02%) YUGE LOSS
This is terrible news and it going to get worse when the other cat gets left out of the bag
$60s HERE WE COME
 




anonymous said:
AbbVie Inc
NYSE: ABBV - Mar 22,
$100.06 USD DOWN $12.39 (11.02%) YUGE LOSS
This is terrible news and it going to get worse when the other cat gets left out of the bag
$60s HERE WE COME
Click to expand...

F YOU !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! THIS IS FAKE NEWS AND ABBV WILL BE AT RECORD HIGH ASAP !!!!
STOP SCARRING US !!!!!!!!! YOU FONY IDIOT !!!!!!!!!!!!!!!!!! ABBV IS DOING FINE !!!!! F YOU
 




AbbVie Inc
NYSE: ABBV - Mar 22
$96.31 USD DOWN -$16.11 (14.33%)

Board of Directors Should Fire RICK RIGHT NOW !
You folks don't realize how close ABBV is to financial disaster.
Humira patent expiration is looming, and there's other trial data similar to Rova T
that will bring Abbvie to its knees. Wait and see !!!!
 




AbbVie has $9.3B in cash on the books. This is offset by $6.42B in current liabilities. On the balance sheet. the debt has been growing. With $70.79B in total assets, balanced by $65.69B billion in total liabilities shows the viability of the company under any number of imagined business contexts. Rick needs to be fired and a shakeup in C Suite is called for. Too many bloodsucking leechs bleeding AbbVie. Time for a change and stockholders will demand it. I dumped 80% @ $115 last Friday as I knew about Rova T bust from inside sources. When the next few waves of bad news hits you're looking at $50-55 stock price.
 




anonymous said:
Agree! Let's hope there isn't anymore serious adverse events with Upadacitinib (ABT 494).Y'all had (2) patients who died in trials on a low dose. Technically, if and when when Abbv launches this, it wont only be competing with Enbrel and Xeljanz, it would also be up against your own Humira. WTF ?
Click to expand...

Heard Upadacitinib had more adverse events. When it rains it pours !!
Theres chatter on the street of Abbvie getting acquired. Heard this years ago and it never panned out
With abbvies poor balance sheet and pending loss of Humira, things can happen in the blink of an eye.
 




anonymous said:
Heard Upadacitinib had more adverse events. When it rains it pours !!
Theres chatter on the street of Abbvie getting acquired. Heard this years ago and it never panned out
With abbvies poor balance sheet and pending loss of Humira, things can happen in the blink of an eye.
Click to expand...


********************
Please refer to your employee's handbook. Under Employee Rules #7 (paraphrasing) '..employees shall not engage in rumor mongering during work hours or in public domains...' You should cease posting total fabrications, possibly formulated by competition, regarding our company. You must realize that what you posted is nonsense.
********************
 




anonymous said:
********************
Please refer to your employee's handbook. Under Employee Rules #7 (paraphrasing) '..employees shall not engage in rumor mongering during work hours or in public domains...' You should cease posting total fabrications, possibly formulated by competition, regarding our company. You must realize that what you posted is nonsense.
********************
Click to expand...

He probably wrote the handbook. You do understand you're responding to a former shot caller from Abbott labs?
 












anonymous said:
AbbVie has $9.3B in cash on the books. This is offset by $6.42B in current liabilities. On the balance sheet. the debt has been growing. With $70.79B in total assets, balanced by $65.69B billion in total liabilities shows the viability of the company under any number of imagined business contexts. Rick needs to be fired and a shakeup in C Suite is called for. Too many bloodsucking leechs bleeding AbbVie. Time for a change and stockholders will demand it. I dumped 80% @ $115 last Friday as I knew about Rova T bust from inside sources. When the next few waves of bad news hits you're looking at $50-55 stock price.
Click to expand...

Offsetting ricks stupidity by shorting this dog with my 8000 shares as many are. Got some nice long calls, may 90s 92.5s and shares at 90.37 quant buy signa. Sell May90 call for 6.90 buy may100 call 2.20 net credit of 4.70.SWEET
 




































Top Bottom
Back
Quote